Michel Vounatsos (Credit: World Economic Forum/Ciaran McCrickard)
July 5, 2022 07:30 PM EDT
Bioregnum
FDA+

Alzheimer's quick OK, take two: FDA of­fers Bio­gen, Ei­sai a short­cut to a pos­si­ble lecanemab ap­proval

Bio­gen CEO Michel Vounatsos is de­part­ing un­der a dark and wide cloud cre­at­ed by the Aduhelm fi­as­co, which es­sen­tial­ly de­stroyed any hope of any sub­stan­tial …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times